Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member

About this update from Lantheus Holdings, Inc.

[{"type":"text","content":"NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus’ Board of Directors (“Board”), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board’s Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. \"We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law and regulation, to the Lantheus Board,\" said Brian Markison, Chairman of the Board of Lantheus. \"As we continue to build value for shareholders through the execution of our strategy, Minnie's deep experience in this industry and specifically her regulatory insight will be invaluable. As Lantheus executes on its purpose to find, fight and follow disease to improve patient outcomes, leveraging her vast experience will be critical to the long-term success of our mission.” \"I am honored to join the Lantheus Board and work alongside such an accomplished group to help guide the future endeavors of the Company,” said Ms. Baylor-Henry. “With its strong executive team, and a clear vision for the future, I believe that Lantheus is well-positioned to continue to deliver on its mission to improve patient outcomes while achieving steady growth.” Ms. Baylor-Henry is the President of B-Henry & Associates, a consulting firm focused on providing regulatory and compliance strategy services to life sciences companies. Prior to assuming her current role, she was the Worldwide Vice-President for Regulatory Affairs for Johnson & Johnson’s Medical Devices & Diagnostics business where she was directly responsible for coordinating the regulatory strategy for the approval of a wide portfolio of products globally. Prior to that Ms. Baylor-Henry was a National Director for Regulatory & Capital Markets Consulting at Deloitte & Touche. From 1991-1999, she worked at the U.S. Food & Drug Administration (“FDA”) where she served in many roles, most notably, FDA’s National Health Fraud Coordinator and, within the Center for Drugs, as the Director of the Division of Drug Marketin...

More updates from Lantheus Holdings, Inc.